drugset / Trial / NCT00696917

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

NCT00696917

Phase 3 Completed 1303 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindPrevention

Summary

This study was conducted to evaluate the lot-to-lot consistency of three lots of HBV-MPL vaccine and to compare their safety and immunogenicity with that of Engerix™-B.

Timeline

Start
1999-04
Primary completion
2000-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Engerix-B Vaccine Intramuscular
Subject HBV-MPL vaccine 208129 Vaccine Intramuscular